Syndax forecasts that 70-80% of KMT2A patients will receive revumenib as post-transplant maintenance within 1-2 years, reflecting rapid adoption and enhanced physician confidence post-Q4 2025.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What is the target steady-state percentage of KMT2A patients you expect to receive post-transplant revumenib maintenance and the timeline to reach it?
Target Percentage:
Current Uptake and Growth Trajectory:
As of Q4 2025, approximately 40% to 45% of KMT2A patients who have undergone transplant have restarted revumenib post-transplant. This is an increase from 35% to 40% reported the previous quarter—demonstrating a rapid adoption rate quarter-over-quarter 342.
Syndax expects this percentage to continue increasing steadily, reflecting a growing phenomenon as more patients complete the engraftment period and more data from leading institutions become available, which supports physicians' confidence in prescribing revumenib maintenance 342.
Timeline to Reach Steady State:
The trajectory to the projected 70%-80% usage is implied to unfold over successive quarters following the observed quarter-over-quarter increases (from 35-40% to 40-45% within a quarter). While an exact timeline is not explicitly stated, the consistent quarter-over-quarter growth and the company’s optimistic guidance suggest reaching the steady-state target in the near to mid-term future—likely within 1 to 2 years post-commercial launch maturity in this setting 12.
Support for longer-term maintenance use also comes from clinician expectations that patients may stay on therapy for 1 to 2 years post-transplant given revumenib’s favorable tolerability and the high risk of relapse in this population 4.
Additional Context:
The maintenance dosing for revumenib is currently aligned with the approved therapy dose (160/270 mg), with ongoing studies to optimize dose in the maintenance setting. Physicians are increasingly comfortable with this dose given increasing usage and emerging real-world data 56.
The increasing adoption of revumenib post-transplant maintenance aligns with Syndax’s broader strategy to expand use of revumenib both in frontline and other combination regimens, potentially increasing the patient pool and treatment duration over time, which supports the sustainability of high post-transplant maintenance percentages 36.
| Metric | Value/Estimate | Supporting Citations |
|---|---|---|
| Current post-transplant use | 40% to 45% | 342 |
| Previous quarter post-transplant use | 35% to 40% | 342 |
| Target steady-state post-transplant use | 70% to 80% | 12 |
| Expected timeline to steady state | Likely within 1-2 years | Implied from trends 21 |
| Typical maintenance therapy duration post-transplant | 1 to 2 years | 4 |
| Maintenance dosing | Same as approved 160/270 mg; dose optimization ongoing | 56 |
Syndax Pharmaceuticals anticipates that the steady-state percentage of KMT2A patients receiving revumenib as post-transplant maintenance could reach between 70% and 80%, up from the current 40% to 45%, as adoption continues to accelerate supported by clinical data and physician experience. The company expects to approach this steady state over the next few quarters to 1-2 years, coinciding with more patients completing the engraftment phase, accumulating real-world evidence, and growing physician comfort. Maintenance therapy may last 1 to 2 years given the high risk of relapse and favorable tolerability profile, supporting a meaningful extension of treatment duration in this high-risk population.
This growing use post-transplant also significantly contributes to the overall Revumenib market penetration and is a key driver behind Syndax’s revenue growth and commercial strategy in KMT2A AML 3421.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Moderna did not set a numeric approval threshold or confirm a 2027 pivotal-data timeline for mRNA-4359 in melanoma. For mRNA-2808, management highlighted safety, response occurrence and durability in heavily pretreated myeloma, but did not provide numeric success criteria or describe a plan to study the therapy earlier in the treatment pathway.
Sources used
Research questionFor mRNA-4359, what efficacy bar would support approval in first- or second-line melanoma, and could it produce pivotal data in 2027? For the T-cell engager in multiple myeloma, what would constitute positive data in a refractory population, and is there a strategy to study it earlier in the treatment pathway?
Answer outline
Adobe is weaving Agentic AI across its major businesses, positioning it as the organizing layer for a next-generation platform that coordinates productivity, creativity, and customer experience. The long-term vision describes an end-to-end agentic system that spans apps, data, and external interfaces, with governance and enterprise context at the core; however, management has not yet disclosed Agentic-specific revenue, emphasizing strategic importance and adoption signals instead.
Sources used
Research questionHow big a factor will Agentic be in Adobe's strategy going forward and what is the long-term path or end state for Agentic?
Answer outline
Synopsys outlines ongoing Factory 2 licensing-royalties shift and a security IP growth path following the Intrinsic ID acquisition, with Investor Day modeling promised but no quantified ramp or TAM in the excerpts.
Sources used
Research questionGreat. Maybe just a couple of quick ones on IP actually. Maybe just preempting the Analyst Day. I wondered, Sassine, if you can maybe just give us a little bit of outline on the speed of shift to the Factory 2 opportunity you outlined with licensing and royalties. And then secondly, it's been about a year, I think, since we've seen the Intrinsic ID acquisition. And I think at the time, you talked about security IP as being a new vector of growth in IP. Just wanted to hear if you could maybe outline the size of that opportunity, how you've seen engagements go and where in particular you think deployments will happen?
Answer outline
Estée Lauder signals an aggressive Makeup revival anchored by M·A·C and Clinique, expanding into fast-growth channels and leveraging social commerce to reaccelerate sales and profitability. The plan combines product innovation, smarter distribution, and selective footprint optimization to sustain growth across North America and key markets like China.
Sources used
Research questionWhat did management say about Makeup growth opportunities and optimization?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Merck's Q2 2026 discussion centers on positioning LIPFENDRA as an add-on to statins, with potential LDL reductions up to 80% when paired with rosuvastatin, and the advancement of two fixed-dose combinations anchored by LIPFENDRA (rosuvastatin and MK-7262). Access via TrumpRx under MFN is planned, with a gradual ramp and emphasis on primary-care education to drive adoption.
Sources used
Research questionWhat did management say about LIPFENDRA combinations and access channels?
Answer outline
Tinder outlines a shift from a photo-centric profile model to richer, contextual profiles and AI-assisted discovery, framed by a 12–18 month roadmap that emphasizes improved recommendations, brand modernization, and live events to drive engagement. The company also explains why the full-year giveback guidance was lowered, citing no revenue impact from the UX/rebrand efforts and a continued emphasis on experimentation within monetization tradeoffs.
Sources used
Research questionPlease elaborate on Tinder's reimagined user experience with more contextual and individually engaging profile elements, and how the Tinder user experience is expected to evolve over the next 12–18 months; also explain the genesis of lowering the full-year giveback guidance and how savings will be reallocated?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi